Center of Gastrointestinal Endoscopy, Hue University Hospital, Huế, Viet Nam; Dipartimento di Scienze Biomediche, Università di Sassari, Sassari, Italy.
Dipartimento di Scienze Biomediche, Università di Sassari, Sassari, Italy.
Int J Antimicrob Agents. 2015 Mar;45(3):244-8. doi: 10.1016/j.ijantimicag.2014.10.019. Epub 2014 Nov 25.
Antimicrobial resistance in Helicobacter pylori has increased worldwide and has become a major cause of treatment failure in many countries, including Vietnam. It is advisable to perform an antibiogram to provide optimal regimens for H. pylori eradication. This study evaluated the rate of antibiotic resistance to the four commonly used antibiotics against H. pylori at a tertiary care hospital in Central Vietnam and analysed point mutations in genes related to clarithromycin (CLA) and levofloxacin (LFX) resistance. A total of 92 H. pylori strains from gastric biopsy specimens were tested; 42.4% were resistant to CLA (primary, 34.2%; secondary, 73.7%), 41.3% to LFX (primary, 35.6%; secondary, 63.2%), 76.1% to metronidazole (MTZ) and 1.1% to amoxicillin. Multidrug resistance was observed in 56.5% (primary, 50.7%; secondary, 78.9%) of isolates (P<0.05). The rate of resistance to LFX was significantly higher in females than males (P<0.05). Most of the CLA- and LFX-resistant strains harboured resistance-associated mutations, with common positions at A2143G and T2182C in the 23S rRNA gene and at Asn-87 or Asp-91 in GyrA. Minimum inhibitory concentrations (MICs) increased in strains carrying quadruple mutations in their 23S rRNA gene and in strains with Asn-87 GyrA mutation (P<0.05). One high-level LFX-resistant strain (MIC=32mg/L) had new mutations with a combination of N87A, A88N and V65I. High resistance rates to CLA, MTZ and LFX discourage standard and LFX-based triple therapies as first-line treatment in Vietnam.
幽门螺杆菌的耐药性在全球范围内有所增加,已成为包括越南在内的许多国家治疗失败的主要原因。建议进行药敏试验,为幽门螺杆菌根除提供最佳方案。本研究评估了越南北中部一家三级保健医院常用的四种抗生素对幽门螺杆菌的耐药率,并分析了与克拉霉素(CLA)和左氧氟沙星(LFX)耐药相关的基因的点突变。共检测了 92 株来自胃活检标本的幽门螺杆菌菌株;42.4%对 CLA(原发,34.2%;继发,73.7%)耐药,41.3%对 LFX(原发,35.6%;继发,63.2%)耐药,76.1%对甲硝唑(MTZ)耐药,1.1%对阿莫西林耐药。56.5%(原发,50.7%;继发,78.9%)的分离株表现出多药耐药(P<0.05)。女性对 LFX 的耐药率明显高于男性(P<0.05)。大多数 CLA 和 LFX 耐药株携带与耐药相关的突变,23S rRNA 基因中的 A2143G 和 T2182C 以及 GyrA 中的 Asn-87 或 Asp-91 为常见突变位置。携带 23S rRNA 基因四重突变或 GyrA 中 Asn-87 突变的菌株 MIC 增加(P<0.05)。一株高水平 LFX 耐药株(MIC=32mg/L)具有新的突变,包括 N87A、A88N 和 V65I。CLA、MTZ 和 LFX 的高耐药率阻碍了标准三联疗法和基于 LFX 的三联疗法作为越南的一线治疗。